Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,885 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,373)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00609817 | Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma | terminated | Phase 1 | 9 | La Jolla Pharmaceutical CompanyINDUSTRY | 1 | Jun 25, 2013 | clinicaltrials |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | terminated | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00354185 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00558727 | Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 12 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | May 10, 2013 | clinicaltrials |
| NCT00452127 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 26 | Genentech, Inc.INDUSTRY | 0 | Jan 28, 2013 | clinicaltrials |
| NCT00060112 | Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma | terminated | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00036855 | Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00030381 | Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00052377 | Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00101244 | SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00003613 | O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma | terminated | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00058773 | Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease(ANGELA) | terminated | Phase 1 | 5 | Baylor College of MedicineOTHER | 1 | Nov 6, 2012 | clinicaltrials |
| NCT00742495 | Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.(BCX1777-108) | terminated | Phase 1 / Phase 2 | 2 | Mundipharma Research LimitedINDUSTRY | 6 | Oct 24, 2012 | clinicaltrials |
| NCT01300793 | Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide(V-RICE) | terminated | Phase 1 | 6 | University of California, San FranciscoOTHER | 1 | Sep 26, 2012 | clinicaltrials |
| NCT00793650 | Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study | terminated | Phase 1 / Phase 2 | 39 | Emory UniversityOTHER | 1 | Aug 30, 2012 | clinicaltrials |
| NCT00383097 | Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma(ALDI) | terminated | Phase 1 | 6 | Baylor College of MedicineOTHER | 1 | May 24, 2012 | clinicaltrials |
| NCT00432419 | Therapeutic Intensification of HIV-associated Non-Hodgkin's Lymphoma by Peripheral Blood Cell Transplantation Following Chemotherapy. | terminated | Phase 1 / Phase 2 | 1 | French National Agency for Research on AIDS and Viral HepatitisOTHER_GOV | 1 | Dec 22, 2011 | clinicaltrials |
| NCT00473551 | Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2011 | clinicaltrials |
| NCT00400764 | A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas | terminated | Phase 1 / Phase 2 | 72 | Genentech, Inc.INDUSTRY | 0 | Nov 23, 2011 | clinicaltrials |
| NCT00880867 | Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma | terminated | Phase 1 | 3 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00050687 | Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies | terminated | Phase 1 / Phase 2 | — | Titan PharmaceuticalsINDUSTRY | 1 | Jan 28, 2011 | clinicaltrials |
| NCT00651443 | Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma | terminated | Phase 1 | 20 | BiogenINDUSTRY | 1 | Jan 7, 2011 | clinicaltrials |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | terminated | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Dec 9, 2010 | clinicaltrials |
| NCT00243763 | TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma | terminated | Phase 1 | 64 | NovartisINDUSTRY | 1 | Nov 23, 2009 | clinicaltrials |
| NCT00471367 | Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877 | terminated | Phase 1 | 44 | AstraZenecaINDUSTRY | 1 | Sep 24, 2009 | clinicaltrials |
| NCT00039754 | A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | — | Poniard PharmaceuticalsINDUSTRY | 0 | Jan 21, 2009 | clinicaltrials |
| NCT00352742 | A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | AttenuonINDUSTRY | 1 | Oct 28, 2008 | clinicaltrials |
| NCT00147485 | A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer | terminated | Phase 1 | 37 | PfizerINDUSTRY | 1 | Aug 18, 2008 | clinicaltrials |
| NCT00234481 | Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia | terminated | Phase 1 | — | ExelixisINDUSTRY | 1 | Jun 4, 2008 | clinicaltrials |
| NCT00057447 | Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients | terminated | Phase 1 / Phase 2 | 24 | InterMuneINDUSTRY | 1 | Nov 1, 2007 | clinicaltrials |
| NCT00100347 | Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors | terminated | Phase 1 | 45 | PRAECIS Pharmaceuticals Inc.INDUSTRY | 1 | Jul 25, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Jun 25, 2013source: clinicaltrials